nitrites and Hypertension, Renal studies

Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)

Hypertension, Renal: Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.

Research Excerpts

Excerpt	Relevance	Reference
"We conclude that hypoxia-induced HTN is associated with depressed NO production and can be mitigated by L-arginine supplementation."	3.70	Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension. ( Bemanian, S; Kivlighn, SD; Ni, Z; Vaziri, ND, 1998)
" Mechanistically, oxidative stress and compromised function of the nitric oxide synthase (NOS) system leading to endothelial dysfunction and reduction in nitric oxide (NO) bioavailability have been widely implicated and associated with development and progression of disease."	2.61	Therapeutic value of stimulating the nitrate-nitrite-nitric oxide pathway to attenuate oxidative stress and restore nitric oxide bioavailability in cardiorenal disease. ( Carlstrom, M; Montenegro, MF, 2019)
"Captopril treatment reversed the increments in pressure back to normal values by the fourth week."	1.33	Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat. ( Al-Shabanah, O; Khattab, MM; Mostafa, A, 2005)
" The role of renal immune cell infiltration, oxidative stress, and nitric oxide bioavailability in the pathogenesis was investigated."	1.33	Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. ( Jung, FF; Manning, J; Stewart, T; Vehaskari, VM, 2005)
"Children attending the above centre for treatment of hypertension."	1.30	Nitric oxide activity in childhood hypertension. ( Dillon, MJ; Goonasekera, CD; Rees, DD; Shah, V, 1997)
"Captopril treatment protected rats receiving L-NAME and none of the captopril-treated rats died."	1.30	Renoprotective effects of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis. ( Eriksson, A; Fyhrquist, F; Holthöfer, H; Miettinen, A; Tikkanen, I; Tikkanen, T; Törnroth, T; Uhlenius, N, 1999)

Research

Studies (19)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Diastolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (26.32)	18.2507
2000's	11 (57.89)	29.6817
2010's	2 (10.53)	24.3611
2020's	1 (5.26)	2.80

Authors	Studies
Park, S	1
Lee, KH	1
Choi, H	1
Jang, G	1
Kang, WS	1
Kim, E	1
Kim, JS	1
Na, CS	1
Kim, S	1
Carlstrom, M	1
Montenegro, MF	1
Rajapakse, NW	1
De Miguel, C	1
Das, S	1
Mattson, DL	1
Sasser, JM	1
Moningka, NC	1
Cunningham, MW	1
Croker, B	1
Baylis, C	3
Al-Nimri, MA	1
Komers, R	1
Oyama, TT	1
Subramanya, AR	1
Lindsley, JN	1
Anderson, S	1
Kawada, N	1
Dennehy, K	1
Solis, G	1
Modlinger, P	1
Hamel, R	1
Kawada, JT	1
Aslam, S	1
Moriyama, T	1
Imai, E	1
Welch, WJ	1
Wilcox, CS	1
Wesseling, S	1
Ishola, DA	1
Joles, JA	1
Bluyssen, HA	1
Koomans, HA	1
Braam, B	1
Khattab, MM	1
Mostafa, A	1
Al-Shabanah, O	1
Stewart, T	1
Jung, FF	1
Manning, J	1
Vehaskari, VM	1
Bivol, LM	1
Berge, RK	1
Iversen, BM	1
Schneider, MP	1
Ge, Y	1
Pollock, DM	1
Pollock, JS	1
Kohan, DE	1
del Castillo, D	1
Raij, L	1
Shultz, PJ	1
Tolins, JP	1
Goonasekera, CD	1
Shah, V	1
Rees, DD	1
Dillon, MJ	1
Ni, Z	1
Bemanian, S	1
Kivlighn, SD	1
Vaziri, ND	1
Uhlenius, N	1
Tikkanen, T	1
Miettinen, A	1
Holthöfer, H	1
Törnroth, T	1
Eriksson, A	1
Fyhrquist, F	1
Tikkanen, I	1
Schmidt, RJ	2
Yokota, S	1
Tracy, TS	1
Sorkin, MI	1
Kim, SW	1
Lee, J	1
Kang, DG	1
Jung, K	1
Kim, NH	1
Suh, SP	1
Choi, KC	1
Kang, YJ	1
Wolf, WC	1
Yoshida, H	1
Agata, J	1
Chao, L	1
Chao, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients[NCT01157234]	Phase 4	32 participants (Actual)	Interventional	2010-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury). (NCT01157234)
Timeframe: Change in Baseline, Month-12

Estimated Glomerular Filtration Rate (ml/Minute) Change From Baseline to Month-12 Between the Groups

Intervention	millimeter, mercury (Least Squares Mean)
Nebivolol	-0.66
Metoprolol	-2.35

The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Mean Arterial Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups

Intervention	percent change (Least Squares Mean)
Nebivolol	2.16
Metoprolol	10.43

"Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.~Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure" (NCT01157234)
Timeframe: Change in Baseline, Month-12

Number of Antihypertensive Drug Classes Change From Baseline to Month-12 Between the Groups.

Intervention	millimeter, Mercury (Least Squares Mean)
Nebivolol	-1.07
Metoprolol	-3.19

Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients < 50 Years Old Compared With Metoprolol in Transplant Recipients < 50 Years Old

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients <50 Years Old Compared With Metoprolol in Transplant Recipients >/= 50 Years Old.

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients >/= 50 Years Old Compared With Metoprolol in Transplant Recipients Age >/= 50 Years Old.

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-twelve of Treatment With Nebivolol in Transplant Recipients >/= 50 Years Old Compared With Nebivolol in Transplant Recipients < 50 Years Old.

Plasma Nitric Oxide Level (Nmol/L) at Month-12 Between the Groups.

Plasma Nitric Oxide Level Change From Baseline to Month 12 Between the Groups.

Intervention	percent change (Least Squares Mean)
Nebivolol	-8.14
Metoprolol	8.70

Intervention	percent change (Least Squares Mean)
Nebivolol < 50 Years Old	51.55
Metoprolol <50 Years Old	-16.64

Intervention	percent change (Least Squares Mean)
Nebivolol <50 Year Old	51.55
Metoprolol >/= 50 Year Old	-17.99

Intervention	percent change (Least Squares Mean)
Nebivolol >/=50 Years Old	-15.25
Metoprolol >/=50 Years Old	-17.99

Intervention	percent change (Least Squares Mean)
Nebivolol >/=50 Years Old	-15.25
Metoprolol <50 Years Old	-16.64

Intervention	nmol/L (Least Squares Mean)
Nebivolol	50.07
Metoprolol	38.13

Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Systolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 of Treatment Between the Groups

Intervention	percent change (Least Squares Mean)
Nebivolol	11.47
Metoprolol	-17.27

Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level (NCT01157234)
Timeframe: Change in Baseline, Month-12

Article	Year
Combined antihypertensive effect of unripe Rubus coreanus Miq. and Dendropanax morbiferus H. Lév. Extracts in 1 kidney-1 clip hypertensive rats and spontaneously hypertensive rats. BMC complementary medicine and therapies, 2021, Oct-28, Volume: 21, Issue:1 Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination;	2021
Exogenous L-arginine ameliorates angiotensin II-induced hypertension and renal damage in rats. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:6 Topics: Albuminuria; Angiotensin II; Animals; Arginine; Blood Pressure; Consciousness; Creatinine; Drug Inte	2008
Asymmetric dimethylarginine in angiotensin II-induced hypertension. American journal of physiology. Regulatory, integrative and comparative physiology, 2010, Volume: 298, Issue:3 Topics: Amidohydrolases; Angiotensin II; Animals; Arginine; Blood Pressure; Fibrosis; Hypertension, Renal; K	2010
Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney international, 2003, Volume: 63, Issue:5 Topics: Animals; Blood Pressure; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Hypertension, Renal	2003
TP receptors regulate renal hemodynamics during angiotensin II slow pressor response. American journal of physiology. Renal physiology, 2004, Volume: 287, Issue:4 Topics: 6-Ketoprostaglandin F1 alpha; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Rece	2004
Resistance to oxidative stress by chronic infusion of angiotensin II in mouse kidney is not mediated by the AT2 receptor. American journal of physiology. Renal physiology, 2005, Volume: 288, Issue:6 Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Aorta; Blood Pressure; Female; Fre	2005
Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat. Kidney & blood pressure research, 2005, Volume: 28, Issue:4 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartate Aminotransferases; Blood Pressure; Body	2005
Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. Kidney international, 2005, Volume: 68, Issue:5 Topics: Animals; Antioxidants; Cell Movement; Cyclic N-Oxides; Female; Hypertension, Renal; Immunosuppressiv	2005
Tetradecylthioacetic acid prevents the inflammatory response in two-kidney, one-clip hypertension. American journal of physiology. Regulatory, integrative and comparative physiology, 2008, Volume: 294, Issue:2 Topics: Animals; Body Weight; Chemokine CCL2; Dinoprost; Disease Models, Animal; Eating; Free Radical Scaven	2008
Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:6 Topics: Animals; Blood Pressure; Diuresis; Endothelin-1; Enzyme Inhibitors; Heart Rate; Hypertension, Renal;	2008
The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1995, Volume: 10, Issue:4 Topics: Animals; Blood Pressure; Disease Models, Animal; Erythropoietin; Hematocrit; Hydrogen-Ion Concentrat	1995
Nitric oxide activity in childhood hypertension. Archives of disease in childhood, 1997, Volume: 77, Issue:1 Topics: Biomarkers; Child; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Hypertension	1997
Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension. Kidney international, 1998, Volume: 54, Issue:1 Topics: Acetamides; Animals; Arginine; Blood Pressure; Disease Models, Animal; Endothelin Receptor Antagonis	1998
Renoprotective effects of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis. Nephron, 1999, Volume: 81, Issue:2 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Pre	1999
Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. The American journal of physiology, 1999, Volume: 276, Issue:5 Topics: Adult; Aged; Arginine; Citrulline; Creatinine; Cyclic GMP; Female; Humans; Hypertension, Renal; Kidn	1999
Erythropoietin does not affect nitric oxide system in rats with chronic renal failure. Journal of Korean medical science, 2000, Volume: 15, Issue:2 Topics: Acetylcholine; Anemia; Animals; Aorta, Thoracic; Body Weight; Erythropoietin; Hypertension, Renal; I	2000
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney international, 2000, Volume: 58, Issue:2 Topics: Adenoviridae; Animals; Blood Pressure; Blood Urea Nitrogen; Cardiomegaly; Cyclic GMP; Fibrosis; Gene	2000
Total nitric oxide production is low in patients with chronic renal disease. Kidney international, 2000, Volume: 58, Issue:3 Topics: Adult; Aged; Arginine; Blood Pressure; Creatinine; Female; Humans; Hypertension, Renal; Kidney Failu	2000

nitrites and Hypertension, Renal